莫沙必利

**莫沙必利**
系统（IUPAC）命名名称
	(RS)-4-amino-5-chloro-2-ethoxy-N-{[4-(4-fluorobenzyl)morpholin-2-yl]methyl}benzamide
临床数据
Drugs.com	国际药品名称
给药途径	口服
识别信息
CAS注册号	112885-41-3
ATC代码	None
PubChem	CID 119584
IUPHAR/BPS	242
ChemSpider	106780
UNII	I8MFJ1C0BY
KEGG	D08236
ChEMBL	CHEMBL60889
化学信息
化学式	C21H25ClFN3O3
摩尔质量	421.893 g/mol
	SMILES Clc1cc(c(OCC)cc1N)C(=O)NCC3OCCN(Cc2ccc(F)cc2)C3; ;
	InChI InChI=1S/C21H25ClFN3O3/c1-2-28-20-10-19(24)18(22)9-17(20)21(27)25-11-16-13-26(7-8-29-16)12-14-3-5-15(23)6-4-14/h3-6,9-10,16H,2,7-8,11-13,24H2,1H3,(H,25,27) ; Key:YPELFRMCRYSPKZ-UHFFFAOYSA-N ;

莫沙必利（英语：Mosapride）是一种消化道促动力药，选择性激动 5-HT₄受体，其主要代谢产物M1还具有5HT₃受体的竞争性拮抗作用。^[1]莫沙必利可以加速胃排空，促进全消化道的蠕动，用来治疗胃炎、胃食管反流病、功能性消化不良和过敏性肠综合征。^[2]^[3]^[4]^[5]枸缘酸盐形式的莫沙必利，由大日本住友制药在1998年以加斯清为商品名上市销售。

参见

↑ Tack, J.; Camilleri, M.; Chang, L.; Chey, WD.; Galligan, JJ.; Lacy, BE.; Müller-Lissner, S.; Quigley, EM.; Schuurkes, J. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders.. Aliment Pharmacol Ther. Apr 2012, 35 (7): 745–67. PMID 22356640. doi:10.1111/j.1365-2036.2012.05011.x.
↑ Odaka T, Suzuki T, Seza A, Yamaguchi T, Saisho H. [Serotonin 5- HT4 receptor agonist (mosapride citrate)]. Nippon Rinsho. August 2006, 64 (8): 1491–4. PMID 16898619 （日语）.
↑ Curran MP, Robinson DM. Mosapride in gastrointestinal disorders. Drugs. 2008, 68 (7): 981–91. PMID 18457463. doi:10.2165/00003495-200868070-00007.
↑ Mizuta Y, Shikuwa S, Isomoto H, Mishima R, Akazawa Y, Masuda J, Omagari K, Takeshima F, Kohno S. Recent insights into digestive motility in functional dyspepsia. Journal of Gastroenterology. 2006 Nov;41(11):1025-40.
↑ Kato S, Morie T, Yoshida N. Synthesis and biological activities of metabolites of mosapride, a new gastroprokinetic agent.Chemical and Pharmaceutical Bulletin (Tokyo). 1995 Apr;43(4):699-702.